Sonnet BioTherapeutics expands SON-1010 trial to combine with trabectedin, targeting improved outcomes in soft-tissue sarcoma patients.
Quiver AI Summary
Sonnet BioTherapeutics Holdings, Inc. has announced an expansion of its Phase 1 SB101 clinical trial of SON-1010, a candidate immunotherapy, to evaluate its effectiveness in combination with the approved chemotherapy drug trabectedin (Yondelis®) for patients with advanced soft-tissue sarcomas. This decision follows positive data from previous trials indicating that SON-1010, administered alone, could provide clinical benefits. The new cohort will assess side effects and immune responses from the combination treatment, building on the established maximum tolerated dose of SON-1010. This trial aims to accommodate 18 patients with specific sarcoma types and will alternate doses of both drugs. Completion of patient enrollment is projected for the first half of 2025, with initial safety data expected later that year. Company executives believe that this combination therapy could enhance tumor response in patients and ultimately lay the groundwork for larger studies in the future.
Potential Positives
- Expansion of the Phase 1 SB101 clinical study of SON-1010 to include a new cohort for combination therapy with trabectedin (Yondelis®), indicating progress and potential for enhanced treatment options in soft-tissue sarcoma (STS) patients.
- Positive initial data suggesting clinical benefit of SON-1010 as a monotherapy provides a strong foundation for its combination evaluation, potentially leading to better outcomes for patients with advanced solid tumors.
- Expected enrollment of up to 18 patients in a significant subset of unresectable, metastatic liposarcoma or leiomyosarcoma, addressing a large unmet need in the treatment of these cancers.
- Topline safety data for the SON-1010 and trabectedin combination anticipated in H2 calendar year 2025, which may provide important insights for future treatment directions and regulatory considerations.
Potential Negatives
- The combination of SON-1010 with trabectedin, although promising, is still in the early stages of evaluation, and the outcomes are uncertain, potentially prolonging the timeline before any effective treatment may become available for patients.
- Topline safety data for the new combination treatment is not expected until H2 2025, which could indicate a delay in advancing the product to later trial phases or market approval.
- The press release emphasizes the reliance on new combination therapies, suggesting that SON-1010 alone may not have sufficient efficacy to advance without additional treatments, raising questions about its standalone viability.
FAQ
What is SON-1010's role in cancer treatment?
SON-1010 is an immunotherapeutic drug being evaluated for its potential to enhance cancer treatments, particularly in soft-tissue sarcoma patients.
How does SON-1010 work with trabectedin?
SON-1010 is being studied in combination with trabectedin to improve treatment outcomes and enhance progression-free survival in patients with advanced soft-tissue sarcomas.
What are the expected results from the Phase 1 SB101 trial?
The trial aims to evaluate the safety and tolerate of SON-1010 and trabectedin, with topline safety data anticipated in H2 2025.
Who will be enrolled in the SON-1010 and trabectedin trial?
The trial expects to enroll up to 18 patients with unresectable, metastatic liposarcoma or leiomyosarcoma for the combination study.
What makes the FHAB technology significant?
The FHAB technology enhances the effectiveness of immunotherapies by improving the targeting and delivery of therapeutic agents like SON-1010 to tumors.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SONN Hedge Fund Activity
We have seen 0 institutional investors add shares of $SONN stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 272,000 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,819,680
- SABBY MANAGEMENT, LLC removed 238,395 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,594,862
- VIRTU FINANCIAL LLC removed 32,687 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $218,676
- GEODE CAPITAL MANAGEMENT, LLC removed 16,704 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $111,749
- VANGUARD GROUP INC removed 14,726 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $98,516
- TOWER RESEARCH CAPITAL LLC (TRC) removed 7,171 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $47,973
- BLACKROCK, INC. removed 520 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $3,478
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis
®
) with the potential to improve trabectedin’s therapeutic window in soft-tissue sarcoma patients
Combined mechanisms have the potential to enhance progression-free survival (PFS) in some of the largest cohorts of patients with soft-tissue sarcoma
Topline safety data of the combination of SON-1010 with trabectedin is expected in H2 calendar year 2025
Sonnet management discusses what this expansion means in a Virtual Investor “What This Means” segment;
Access here
PRINCETON, NJ, Jan. 21, 2025 (GLOBE NEWSWIRE) --
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today an expansion of its Phase 1 SB101 clinical study of SON-1010 (IL12-F
H
AB) in adult patients with advanced solid tumors to add a new cohort to evaluate the effect of SON-1010 in combination with trabectedin (Yondelis
®
), following the
successful completion of monotherapy dose escalation
. This expansion will explore the immune-oncology impact of SON-1010 at the maximum tolerated (MTD) dose of 1200 ng/kg in combination with trabectedin, which is an approved chemotherapeutic drug for certain advanced soft-tissue sarcomas (STS). Patients with STS could potentially benefit from an enhanced local immune response in the tumor microenvironment (TME). Enrollment in this cohort is underway and is expected to be completed in H1 calendar year 2025. Topline safety data of the combination with trabectedin is expected in H2 calendar year 2025; no new safety concerns have been reported to date. Additionally, the Company announced the release of a “What This Means” segment to discuss the expansion of the Phase 1 clinical study which is now available
here
.
“The Sarcoma Oncology Center is pleased to have been able to enroll most of the patients in Sonnet’s Phase1 SB101 study to date, with the majority of the patients having STS,” commented Dr. Sant Chawla, Principal Investigator at the Sarcoma Oncology Center in Santa Monica, California. “Additionally, as we have contributed to the development of trabectedin over the years, we were excited to see its approval in early 2024 as a monotherapy in the second-line treatment for two of the most common types of sarcoma — liposarcoma and leiomyosarcoma. While the trabectedin approval was based on several clinical trials in sarcoma, we believe a large unmet need remains for the treatment of STS. We believe that combining trabectedin with SON-1010 has the potential for a natural synergistic effect of the two mechanisms of action.”
The Company expects to enroll up to 18 patients with unresectable, metastatic liposarcoma or leiomyosarcoma in this open-label, single-arm expansion cohort. The patients will be treated with SON-1010 in combination with the standard 21-day trabectedin cycles, alternating the dosing of the two drugs. This number of subjects may be needed to see a statistical benefit in the response using the standard RECIST paradigm. The primary outcome measures for the Phase 1 SB101 trial are the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SON-1010 and to establish the MTD, which has been set at 1200 ng/kg. The Company believes the results of this expansion cohort could position SON-1010 for a larger Phase 2 study that could establish the combination of SON-1010 and trabectedin as a new and potentially improved treatment for STS.
“The ability to assess earlier-stage patients is an exciting opportunity to evaluate the potential for SON-1010 to turn ‘cold’ tumors ‘hot’,” said Richard Kenney, M.D., Sonnet's Chief Medical Officer. “Most Phase 1 studies in the oncology space are done in patients with advanced disease, whose immune systems may not respond optimally after multiple types of chemotherapy. Trabectedin’s approval as a single agent second-line therapy in STS provides access to patients at an earlier stage with an underlying immune response that may be more robust.”
“The Sonnet team has been studying the efficacy and safety of SON-1010 as a single agent, which has thus far suggested clinical benefit when administered as a monotherapy in patients with advanced solid tumors,” said Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. “Further, we believe this synergy could improve the response in a serious type of cancer at an earlier stage of disease, which could open up another potential opportunity for partnering.”
SON-1010 is the Company’s proprietary version of recombinant human interleukin-12 (rhIL-12), configured using genetic fusion to Sonnet's Fully Human Albumin Binding (F
H
AB
®
) platform, which extends the half-life and bioactivity of the IL-12 component due to binding native albumin in the serum. Albumin naturally targets the TME by strong binding to gp60 and Secreted Protein Acidic and Rich in Cysteine (SPARC). The majority of patients enrolled to date in the Phase 1 SB101 trial have STS, which has a known potential for an enhanced response to immunotherapy.
Trabectedin is an alkylating DNA-binding agent that was approved as a second-line treatment in early 2024 for patients with unresectable, metastatic liposarcoma or leiomyosarcoma who have received a prior anthracycline-containing regimen. It is also known to activate tumor macrophages into a pro-inflammatory phenotype. The Company believes that SON-1010 has the potential to complement that activity by activating the NK and T cells in the TME to secrete more interferon-gamma (IFN
γ
) which is considered to be important for anti-tumor control.
For more information about the Phase 1 SB101 trial in adult patients with advanced solid tumors visit
www.clinicaltrials.gov
and reference identifier
NCT05352750
.
SON-1010 is also being evaluated in a Phase 1b/2a dose-escalation and proof-of-concept study (SB221) in combination with SON-1010 and atezolizumab (Tecentriq
®
) (in collaboration with Genentech, a member of the Roche Group), which is focused on platinum-resistant ovarian cancer (PROC) (
NCT05756907
). Enrollment remains ongoing and an update on safety at the MTD in that trial is expected in Q1 calendar year 2025.
About SON-1010
SON-1010 is a candidate immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3. This single-chain antibody fragment was selected to bind albumin both at normal pH, as well as at the acidic pH typically found in the TME. The F
H
AB technology targets tumor and lymphatic tissue, providing a mechanism for dose sparing and an opportunity to improve the safety and efficacy profile of not only IL-12, but a variety of potent immunomodulators that can be linked using the platform. Interleukin-12 can orchestrate a robust immune response to many cancers and pathogens. Given the types of proteins induced in the TME, such as the Secreted Protein and Rich in Cysteine (SPARC) and glycoprotein 60 (GP60), several types of cancer, such as non-small cell lung cancer, melanoma, head and neck cancer, sarcoma, and some gynecological cancers are particularly relevant to this approach. SON-1010 is designed to deliver IL-12 to local tumor tissue, turning ‘cold' tumors ‘hot' by stimulating IFN
γ
, which activates innate and adaptive immune cell responses and increases the production of Programed Death Ligand 1 (PD-L1) on tumor cells.
About the Phase 1 SB101 Trial
This first-in-human study is primarily designed to evaluate the safety of multiple ascending doses of SON-1010 in cancer patients and is being conducted at several sites across the United States. While the optimal dose is unknown at this stage, the potential to target the tumors, the extended PK mechanism, and our preclinical data suggest the therapeutic dose may be lower compared to native human IL-12. The study, utilizing a standard 3+3 oncology design in at least five cohorts, established the MTD at 1200 ng/kg using subcutaneous injections of SON-1010 every 3 to 4 weeks. The primary endpoint explores the safety and tolerability of SON-1010, with key secondary endpoints intended to measure PK, PD, immunogenicity, and anti-tumor activity. This study will form the basis for potential combinations with other types of immunotherapies and the future development of bispecific candidates using the F
H
AB platform.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet is an oncology-focused biotechnology company with a proprietary platform for developing targeted biologic drugs with single or bifunctional action. Known as F
H
AB (Fully Human Albumin-Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's F
H
AB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. F
H
AB platform is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.
Sonnet’s lead program, SON-1010, or IL-12-F
H
AB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study through a Master Clinical Trial and Supply Agreement, along with ancillary Quality and Safety Agreements, with Roche in combination with atezolizumab (Tecentriq®) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-F
H
AB-IL15 for solid tumors, in collaboration with the Sarcoma Oncology Center to commence an investigator-initiated and funded Phase 1/2a study for the treatment of pancreatic cancer.
The Company’s SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). SON-080 demonstrated encouraging results in a Phase 1b/2a clinical trial, being well tolerated with no evidence of a pro-inflammatory cytokine response. In October 2024, Sonnet announced an India license agreement with Alkem Laboratories, Inc. who will assume responsibility for advancing development of the SON-080 program into a Phase 2 study in DPN.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the outcome of the Company’s clinical trials, the Company's cash runway, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Investor Relations Contact:
JTC Team, LLC
Jenene Thomas
908-824-0775
SONN@jtcir.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
